Cargando…

In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study

This single-center, observational study analyzed the association between plasma concentration of sorafenib and its safety and efficacy in Chinese patients with metastatic renal cell carcinoma (mRCC). Adult patients with RCC (n = 94), treated with sorafenib were enrolled between January 2014 and Janu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mai, Haixing, Huang, Jun, Zhang, Yuanyuan, Qu, Nang, Qu, Hengyan, Mei, Guo-hui, Liu, Jiannan, Xu, Xiaojie, Chen, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522161/ https://www.ncbi.nlm.nih.gov/pubmed/28404979 http://dx.doi.org/10.18632/oncotarget.16465

Ejemplares similares

Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma
por: Zhang, Yuanyuan, et al.
Publicado: (2018)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study
por: Zhang, Hai-Liang, et al.
Publicado: (2015)

Quantification of Plasma Cell-Free DNA(1) in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma
por: Feng, Gang, et al.
Publicado: (2013)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma
por: Kasahara, Ryo, et al.
Publicado: (2017)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

AB186. The efficacy and safety of sorafenib in Chinese patients with metastatic renal cell carcinoma and prognostic factors related to its efficacy
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
por: Ye, Ding-Wei, et al.
Publicado: (2014)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

Stabilization of metastatic myxopapillary ependymoma with sorafenib
por: Fegerl, Gundula, et al.
Publicado: (2012)

Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib
por: Li, Zhi Yong, et al.
Publicado: (2016)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
por: Randrup Hansen, Caroline, et al.
Publicado: (2017)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
por: Cai, Wen, et al.
Publicado: (2017)

Development and validation of a HPLC-MS/MS method with electrospray ionization for quantitation of potassium oxonate in human plasma: Application to a pharmacokinetic study
por: HAO, GUANGTAO, et al.
Publicado: (2013)

Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study
por: Wei, Di, et al.
Publicado: (2019)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
por: Qu, Zhen, et al.
Publicado: (2016)

Development of Nephrotic Syndrome after Administration of Sorafenib in a Case of Metastatic Renal Cell Carcinoma
por: Okuno, Yumiko, et al.
Publicado: (2011)

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
por: Pantaleo, Maria Abbondanza, et al.
Publicado: (2012)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
por: Zhang, Hailiang, et al.
Publicado: (2009)

The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
por: Ho, Thai H, et al.
Publicado: (2015)

Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre
por: Saxena, Mohith, et al.
Publicado: (2018)

A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib
por: Gunaldi, Meral, et al.
Publicado: (2014)

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
por: Zhang, Hai-Liang, et al.
Publicado: (2017)

Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study
por: Guo, Fang, et al.
Publicado: (2015)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
por: Bhatia, Shailender, et al.
Publicado: (2014)

A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
por: Wang, Hai-Tao, et al.
Publicado: (2019)

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
por: Martín-Aguilar, Ana Elena, et al.
Publicado: (2021)

Sorafenib in metastatic MTC – a case report and minireview of the literature
por: Petrova, Mila, et al.
Publicado: (2010)

Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells
por: Yang, Qu, et al.
Publicado: (2021)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
por: Eto, Masatoshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1acck9kkvhft8lr34dl60mafi8